Wspólnotowy Serwis Informacyjny Badan i Rozwoju - CORDIS

FP7

COATIM Streszczenie raportu

Project ID: 278425
Źródło dofinansowania: FP7-HEALTH
Kraj: Belgium

Periodic Report Summary 3 - COATIM (Development of antibiofilm coatings for implants)

Project Context and Objectives:
Certain microorganisms are capable of growing in layers, forming biofilms on medical surfaces, like implants, heart valves, etc... Biofilm-associated infections on implants are responsible for 15-25 % of implant failures, as biofilms are resistant to most of the conventional anti-microbial agents. To improve integration of bone implants novel porous materials have been used as scaffolds that ironically serve as an ideal niche for microbial growth.

So far, implant coatings with biocidal properties have been generated, which release silver ions or conventional antibiotics to inhibit biofilm formation. The EU-funded project COATIM (Development of antibiofilm coatings for implants) initiative aims to develop the next generation of implant coatings containing novel potent proprietary anti-biofilm molecules (ABMs).

Project Results:
During COATIM, five molecules showing the most promise in inhibiting bacterial and fungal growth along with two standard anti-microbial compounds (vancomycin and caspofungin) were selected by the consortium members. These selected molecules were grafted on small titanium implant substrates and their anti-microbial activity was evaluated in vitro and in vivo, alongside their in vitro osseointegration capacity. Researchers also evaluated their remaining activity following sterilisation procedures. Finally, the best performing molecule-coatings were applied on complex orthopaedic and dental implants and osseointegration was assessed in vivo using rat and rabbit models, respectively. No detrimental effects of the coatings on osseointegration were observed.

Potential Impact:
The need to resolve biofilm-associated infections is urgent in order to reduce the necessity for revision surgery. Besides higher medical costs, such infections lead to significant pain and distress in patients. Our study outcomes are expected to help, avoid or reduce this unnecessary suffering.

Kontakt

Myriam Witvrouw, (Advisor European Project Management)
Tel.: +32 16 32 06 23
Faks: +32 16 32 65 15
Adres e-mail

Tematy

Life Sciences
Numer rekordu: 183941 / Ostatnia aktualizacja: 2016-06-09
Źródło informacji: SESAM